Exhibit 99.1

 

Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

 

 

 

Friday, March 30, 2018 2:00 pm PDT

 

IRVINE, Calif. -- (BUSINESS WIRE) -- Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter and year ended December 31, 2017 and provided a corporate update.

 

“The past year was a productive year for us,” said Gregory J. Flesher, CEO of Novus Therapeutics.  “We completed the merger with Tokai Pharmaceuticals, Inc. and embarked on a mission to develop a novel, first-in-class treatment option for otitis media.  Over the last several months we have made good progress on OP-02 and now plan to initiate our phase 1 clinical program in the second half of this year.”

  

Fourth Quarter and Full-Year 2017 Financial Results

 

For the three-month period ended December 31, 2017, Novus reported a net loss of $2.1 million, or $0.30 loss per share, compared to a net loss of $1.5 million, or $0.57 loss per share, for the same period in 2016.  For the twelve-month period ended December 31, 2017, Novus reported a net loss of $13.1 million, or $2.30 loss per share, as compared to a net loss of $5.7 million, or $2.46 loss per share, for the same period in 2016.  The company had $17.2 million in cash and cash equivalents as of December 31, 2017.

 

Research and development (R&D) expenses were $0.5 million during the three-month period ended December 31, 2017, compared to $0.9 million for the same period in 2016. R&D expenses for the twelve-month period ended December 31, 2017 were $2.0 million, compared to $3.2 million for the same period in 2016. R&D expenses were lower in 2017 primarily due to decreased spending on the foam program (OP-01), offset by wind down costs incurred for legacy Tokai programs.  We expect research and development expenses to increase in subsequent periods as we advance our surfactant program (OP-02).

 

General and administrative (G&A) expenses were $1.6 million during the three-month period ended December 31, 2017, compared to $0.6 million for the same period in 2016.  G&A expenses for the twelve-month period ended December 31, 2017 were $11.1 million, compared to $1.9 million for the same period in 2016.  G&A expenses were higher in 2017 primarily due to the recognition of merger related expenses, an increase in administrative costs associated with operating a public company, and the ongoing legal costs related to Tokai’s stockholder litigation.

 

Recent Events

 

In March 2018, the company announced that it had concluded its offering of common stock under its “at-the-market” offering facility.  The company raised approximately $8.5 million in gross proceeds under the facility.

 

Anticipated Milestones

 

 

Mid-2018Manufacture OP-02 drug product (cGMP)

 


Exhibit 99.1

 

 

2H 2018Initiate OP-02 phase 1 study in healthy adults (safety/tolerability)

 

1H 2019Initiate OP-02 phase 1 study in children with otitis media with effusion (explore efficacy)

 

1H 2019Initiate OP-02 phase 1 study in adults with acute otitis media (explore efficacy)

 

1H 2019Data from phase 1 studies

 

About OP-02

 

OP-02 is a drug-device combination product comprised of a novel formulation of dipalmitoylphosphatidylcholine (DPPC) and cholesteryl palmitate (CP) suspended in a propellant. The product is administered intranasally via a metered dose inhaler and is intended to be used to restore the normal physiologic activity of the Eustachian tube (ET).  Together DPPC and CP effectively absorb to the air-liquid interface of the mucosa and reduce the interfacial surface tension of the ET, which reduces passive pressure required for the ET to open. In other words, OP-02 promotes ‘de-sticking’ of the ET so that ventilation and drainage of the middle ear may occur.

 

About Novus Therapeutics

 

Novus Therapeutics is a specialty pharmaceutical company focused on developing products for disorders of the ear, nose, and throat (ENT).  Novus has two technologies, each that has the potential to be developed for multiple ENT indications.  The company’s lead product (OP-02) is a surfactant-based, combination drug product being developed as a potential first-in-class treatment option for patients at risk for or with otitis media (“OM”) (middle ear inflammation with or without infection).  Globally, OM affects more than 700 million adults and children every year.  OM is a common disorder seen in pediatric practice, and in the United States is the most frequent reason children are prescribed antibiotics and undergo surgery.  Novus also has a foam-based drug delivery technology (OP-01), which may be developed in the future to deliver drugs into the ear, nasal, and sinus cavities.  For more information please visit novustherapeutics.com.

 

Forward-Looking Statements

 

Any statements in this press release about the company’s future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, the review of strategic alternatives and the outcome of such review and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “may,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, expectations regarding the timing for the commencement and completion of our clinical trials and our ability to accelerate the development of our drug candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the sufficiency of the company’s cash resources; the ability to timely develop and manufacture clinical batches of our study drugs; the ability to obtain necessary approvals to commence additional clinical trials; whether data from early clinical trials will be indicative of the data that will be obtained from future clinical trials; whether the results of clinical trials will warrant submission for regulatory approval of any investigational product, any such submission will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies and, if we are able to obtain such approval for an investigational product, it will be successfully distributed and marketed. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.


 


Exhibit 99.1

 

NOVUS THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

 

 

 

December 31,

 

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

17,233

 

 

$

1,103

 

Restricted cash

 

 

70

 

 

 

14

 

Prepaid expenses and other current assets

 

 

1,697

 

 

 

33

 

Total current assets

 

 

19,000

 

 

 

1,150

 

Property and equipment, net

 

 

25

 

 

 

31

 

Goodwill

 

 

1,867

 

 

 

 

Other assets

 

 

 

 

 

15

 

Total assets

 

$

20,892

 

 

$

1,196

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

Accounts payable

 

$

418

 

 

$

338

 

Accrued severance

 

 

668

 

 

 

 

Accrued expenses and other liabilities

 

 

354

 

 

 

113

 

Convertible notes

 

 

 

 

 

3,447

 

Total liabilities

 

 

1,440

 

 

 

3,898

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value, 5,000,000 shares authorized and none    issued and outstanding at December 31, 2017; $0.001 par value, 44,140,630 shares authorized and 19,533,331 shares issued and outstanding at December 31, 2016 (1)

 

 

 

 

 

19

 

Common stock, $0.001 par value, 200,000,000 shares authorized and      7,110,414 shares issued and outstanding at December 31, 2017;

$0.001 par value, 31,476,614 shares authorized and 394,306 shares     issued and outstanding at December 31, 2016 (2)

 

 

7

 

 

 

 

Additional paid-in capital

 

 

46,951

 

 

 

11,378

 

Receipts on account of preferred stock

 

 

 

 

 

291

 

Accumulated deficit

 

 

(27,506

)

 

 

(14,390

)

Total stockholders’ equity (deficit)

 

 

19,452

 

 

 

(2,702

)

Total liabilities and stockholders’ equity (deficit)

 

$

20,892

 

 

$

1,196

 

 

 

(1)

Number of shares as of December 31, 2016, has been retroactively adjusted to reflect the effect of the conversion ratio of the Reverse Merger consummated on May 9, 2017.

 

(2)

Number of shares has been retroactively adjusted to reflect the effect of the conversion ratio of the Reverse Merger consummated on May 9, 2017, and the reverse stock-split effected on May 11, 2017.


 


Exhibit 99.1

 

NOVUS THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS

(In thousands, except share and per share data)

 

 

 

Year Ended

December 31,

 

 

 

2017

 

 

2016

 

Operating expenses

 

 

 

 

 

 

 

 

Research and development

 

$

2,022

 

 

$

3,191

 

General and administrative

 

 

11,099

 

 

 

1,937

 

Total operating expenses

 

 

13,121

 

 

 

5,128

 

Loss from operations

 

 

(13,121

)

 

 

(5,128

)

Other income (expense), net

 

 

5

 

 

 

(527

)

Net loss and other comprehensive loss

 

$

(13,116

)

 

$

(5,655

)

Net loss per share, basic and diluted

 

$

(2.30

)

 

$

(2.46

)

Weighted-average common shares outstanding,
basic and  diluted

 

 

4,677,610

 

 

 

382,747

 

 

 

 

Investor Contacts

 

Novus Therapeutics, Inc.

Investor Relations

Tel: (949) 238-8090

investors@novustherapeutics.com

 

 

 

 

 

 

View differences made from one to another to evaluate Novus Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Novus Therapeutics, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account